TissueLabs has closed a pre-seed round of $800,000 led by Mergus Ventures, with notable contributions from MIT Angels, among other funds and private investors. Concurrently, the company proudly unveils its state-of-the-art biofabrication hub in Bellinzona, advancing its mission to revolutionize healthcare through tissue engineering.
The investment will expedite TissueLabs' research and development initiatives, particularly enhancing its proprietary technology platforms, expanding its team, and establishing strategic partnerships within the biotechnology sector. Importantly, part of the funds has been specifically allocated for setting up the new hub in Bellinzona, highlighting the company's commitment to fostering innovation in an emerging biotech cluster. TissueLab’s mission is to produce synthetic tissues and organs for therapeutic applications. Its product portfolio includes advanced 3D bioprinters, tissue-specific biomaterials, and specialized software.
TissueLabs' new facilities, located in the Gallera building at the heart of Bellinzona, comprise two independent state-of-the-art laboratories for production and research, alongside modern offices and meeting spaces. Dr. Gabriel Liguori, CEO and Founder of TissueLabs, expressed enthusiasm about this dual announcement: "We are immensely grateful for the trust placed in us by Mergus Ventures, MIT Angels, and all our investors. This investment, alongside our new facilities in Bellinzona, represents a significant leap towards achieving our vision."
The Bellinzona hub will play a crucial role in scaling up the production of TissueLabs' innovative products, such as their 3D bioprinters and tissue-specific biomaterials, and the development of innovative solutions aimed at clinical applications. Dr. Tácia Liguori, CSO at TissueLabs, shared her excitement: "Our shiny new labs aren't just for dreaming about what's next; they're where we roll up our sleeves and actually build the future. The chance to speed up our work on new treatments has never felt more real."
(Press release / SK)
Please login or sign up to comment.
Commenting guidelines